This concern, combined with the risk of patent cliff and compounded pharmaceuticals/grey market peptides on GLP-1 manufacturer economics, caused us to exit the basket in November 2024
Novel GLP-1R agonists currently under development include HRS9531, a dual GLP-1/GIP receptor agonist being evaluated in overweight or obese individuals with T2DM, which has shown promising results in a Phase 2 study [172]
1 A subset of this, prescription drug spending, was estimated to be $487 billion in 2024, an industry-wide 11.4% increase over the previous year, compared to 7% for Navitus clients
It's not going to erase decades overnight, but it's like giving your skin a daily dose of youth-preserving nutrients
These bonds are part of the aging process known as glycosylation (Advanced Glycoslation End Products or AGEs)
BPC-157 10mg | Recovery And Healing Peptides is strictly for research use only